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Abstract
Background: In general, point-of-care (POC) tests for Chlamydia trachomatis (Ct) show disappointing test performance,
especially disappointing sensitivity results. However, one study sponsored by the manufacturer (Diagnostics for the Real
World) reported over 80% sensitivity with their Chlamydia Rapid Test (CRT). We evaluated the performance of this CRT in a
non–manufacturer-sponsored trial.
Methods: Between July 2009 and February 2010, we included samples from 912 women in both high- and low-risk clinics
for sexually transmitted infections (STIs) in Paramaribo, Suriname. Sensitivity, specificity, positive- and negative predictive
values (PPV and NPV) for CRT compared to NAAT (Aptima, Gen-Probe) were determined. Quantitative Ct load and human
cell load were determined in all CRT and/or NAAT positive samples.
Results: CRT compared to NAAT showed a sensitivity and specificity of 41.2% (95% CI, 31.9%–50.9%) and 96.4% (95% CI,
95.0%–97.5%), respectively. PPV and NPV were 59.2% (95% CI, 47.5%–70.1%) and 92.9% (95% CI, 91.0%–94.5%), respectively.
Quantitative Ct bacterial load was 73 times higher in NAAT-positive/CRT-positive samples compared to NAAT-positive/CRT-
negative samples (p,0.001). Human cell load did not differ between true-positive and false-negative CRT results (p=0.835).
Sensitivity of CRT in samples with low Ct load was 12.5% (95% CI, 5.2%–24.2%) and in samples with high Ct load 73.5% (95%
CI, 59.9%–84.4%).
Conclusions: The sensitivity of CRT for detecting urogenital Ct in this non–manufacturer-sponsored study did not meet the
expectations as described previously. The CRT missed samples with a low Ct load. Improved POC are needed as meaningful
diagnostic to reduce the disease burden of Ct.
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Introduction
Urogenital chlamydia is the most prevalent, curable bacterial
sexually transmitted infection (STI) worldwide [1], with a
significant public health burden, especially in young women [2].
The causative bacterium, Chlamydia trachomatis (Ct) causes a high
rate of asymptomatic infections [3] and is associated with adverse
outcomes like infertility, ectopic pregnancy and pelvic inflamma-
tory disease (PID) [4]. To reduce transmission and late
complications, active case finding and early treatment are critical
strategies. The standard diagnostics are Nucleic Acid Amplifica-
tion Tests (NAAT), but they are expensive and require
sophisticated laboratory conditions [5]. This makes NAAT
unsuitable for the detection of Ct for most low-resource settings
[6]. Therefore the World Health organization (WHO) has
launched a priority program that is designated to develop
affordable and reliable point-of-care (POC) tests for STIs that
are predominant in low resource countries [http://www.who.int/
std_diagnostics]. In this program, WHO has formulated the
ASSURED criteria that POC tests have to meet: Affordable,
Sensitive, Specific, User-friendly, Robust and rapid, Equipment-
free, Deliverable to those who need them [7]. The POC test result
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prompt treatment. This is especially important where patient
return for treatment is low. It is estimated that a POC test of
moderate sensitivity (63%) combined with immediate treatment
on-site may lead to the treatment of more infected individuals than
an ultra-sensitive and specific NAAT alone when patient return is
low [8]. Moreover, counselling messages are most efficient when a
diagnosis can be communicated during the same consultation [9].
These advantages are relevant for industrialized countries as well,
even if POC tests have a lower sensitivity than standard NAAT.
To date, POC tests for urogenital chlamydia show disappoint-
ing test characteristics, especially low sensitivity. In a recent
evaluation, three POC tests for urogenital chlamydia, currently on
the market, showed poor sensitivity between 12% and 17% in a
non–manufacturer-sponsored clinical study [10]. In contrast, one
POC test for urogenital chlamydia (Diagnostics for the Real
World, Cambridge, UK) especially developed for low-resource
countries has an asserted sensitivity of over 80% [11]. A
manufacturer-sponsored diagnostic field study in the Philippines
revealed sensitivities of 71% and 87% among women at high risk
and low risk for STI, respectively [12]. Suriname, South America,
is a low-resource country and affordable and reliable diagnostics to
detect Ct are urgently needed. Therefore, we aimed to evaluate
the performance of this promising POC test in two outpatient
clinics in Suriname, with the objective to use this test for
intervention of the chlamydia epidemic.
Methods
Study sites and population
The study was approved by the ethical committee of the
Ministry of Health of the Republic of Suriname (VG010-2007)
and the ethical committee of the Academic Medical Centre,
University of Amsterdam, the Netherlands (MEC07/127). Patients
were recruited at two sites in Paramaribo, Suriname:
1) The Dermatological Service, an integrated outpatient clinic
that offers free-of-charge examination and treatment of STIs
and infectious skin diseases like leprosy and leishmaniasis. All
consecutive women who visited for an STI check-up were
asked to participate in the study and were considered to be at
high-risk for STI.
2) The Lobi Foundation is a center for birth control and sexual
health. As women who visit this clinic do not attend primarily
to be checked for STI, these participants were considered to
be at low risk for STI.
Recruitment took place between July 2009 and February 2010.
Exclusion criteria were: use of antibiotics in the past 7 days, age
younger than 18 years and previous participation. After written
informed consent, patients were given a unique code to
participate anonymously. Participants were interviewed about
demographic characteristics, including self-reported ethnicity as
Suriname is a multiethnic society, with many ethnic groups such
as Creoles and Maroons (both descendants from the African
diaspora due to slave trade), Hindustani, Javanese, and Chinese
(all descendants from labor immigrants), Caucasians (descendants
from Dutch farmers), indigenous Amerindian people and Mixed
race persons. Moreover, participants were asked about willing-
ness to wait for POC test results, although in our study
participants did not receive the results from POC, and if they
used any products for vaginal hygiene like douches, herbs, or
other home products, and if so, in what frequency. Data were
entered into an MS Access database.
Specimen collection and testing procedures
Nurse-collected vaginal swabs were obtained blindly for the
Chlamydia Rapid Test (CRT) (Diagnostics for the Real World
(Europe), Cambridge, UK) and NAAT (Aptima, Gen-Probe, San
Diego, USA) testing using a cross-over model. This means that in
the first half of the included women theswabfor the CRT was taken
first and the second of the included women NAAT was taken first.
Nurses were trained to collect the swabs before routine speculum
examination was performed. A minimum period of 10 times for
CRT and 10 seconds for NAAT of contact between the tip of the
swab and the vaginal wall in a rotating motion was ensured. CRT
was immediately performed according to the manufacturer’s
instructions on-site in the laboratory. All technicians that performed
the CRT were trained with proficiency panels as provided and
instructed by the manufacturer. Technicians did not receive
information about the participant. The test results were interpreted
and recorded by two laboratory technicians separately. CRT results
were defined as indeterminate when the laboratory technicians
reported discordant results or when CRT failed (i.e. control line did
not appear). The samples for NAAT testing were collected
according to the manufacturer’s instructions, and shipped to the
Public Health Laboratory in Amsterdam where they were tested
within 50 days after collection. NAAT test results were communi-
cated with the two recruitment sites in Suriname and participants
witha positive-Ct NAAT weretreated with doxycycline 100 mg bid
for 7 days at Lobi Foundation and 10 days bid at the
Dermatological Service or, in case of (possible) pregnancy, with a
single 1000 mg oral dose of azithromycin.
Chlamydia Rapid Test
The CRT was performed as described previously [13]. Version
6.1 of the Chlamydia Rapid Test (Professional use) (P/N 1200-20)
instructions for use (C03-0008) was used. Shortly, each swab was
subjected to extraction by sequential addition of 400 ml of reagent
1, 300 ml of reagent 2, and 100 ml of reagent 3 to the swab in a
tapered sample preparation tube, with gentle mixing between
additions. The sample preparation reagents were administered
with unit dose pipettes. The extraction tube was then capped and
used as a dropper to deliver 5 drops (approximately 100 ml) of the
extracted sample to a tube containing the lyophilized amplification
and detection reagents. The resulting mixture was agitated gently
until a clear pink solution was obtained, after which the test strip,
coated with a monoclonal antibody to chlamydial lipopolysaccha-
ride (LPS) and including a procedural control, was added to the
solution and allowed to stand for 25 minutes before the result was
read. Each swab was subjected to one extraction. The test strip
was used in the interpretation of the result; a clearly visible test line
indicated a positive result, provided that the control line was also
visible on the test strip.
NAAT testing
For NAAT testing, the monospecific Aptima chlamydia assay
for the detection of Chlamydia trachomatis rRNA (Gen-Probe Inc.,
San Diego, USA) was used with the accompanying vaginal swab
specimen collection kit. The protocols described in the package
inserts were followed. Technicians performing NAAT were
blinded to the results of the POC-Ct and did not receive clinical
information. This NAAT is an FDA-approved commercial test
and was used to estimate the Ct prevalence at both study sites.
Quantitation of Ct load and HLA
Quantitative Ct load was determined for samples with a
discrepant test result between CRT and NAAT, and for samples
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PCR targeting the cryptic plasmid [14]. Ct load was expressed as
inclusion forming units (IFU) based on defined serial dilutions of
Ct cultured in human cells with over .90% infected HeLa cells of
100 IFU to 0.001 IFU taking into account also DNA from non-
viable Ct particles. The human cell load was assessed by
determination of human HLA copies in combination with a
defined serial dilution of quantified human DNA using the fol-
lowing primer probe combination: HLA-F 59-TTG-TAC-CAG-
TTT-TAC-GGT-CCC-39 HLA-R 59- TGG-TAG-CAG-CGG-
TAG-AGT-TG,-3 and HLA-Probe 59-FAM- TTC TAC GTG
GAC CTG GAG AGG AAG GAG -BHQ1-39. By using a
chlamydial and a human target, the average chlamydial/human
cell ratio, and IFU/swab were calculated [10].
Statistical analysis
To evaluate the performance of CRT compared to NAAT
sensitivity, specificity, positive predictive value (PPV) and negative
predictive value (NPV) were calculated using standard methods.
Specimens with indeterminate results by CRT were excluded. An
independent t-test was used to compare log-transformed Ct loads
between true-positive and false-negative CRT results. Analyses
were performed with SPSS package version 19.0 (SPSS Inc.,
Chicago, IL).
The study has been reported according to the STARD checklist
for the reporting of studies of diagnostic accuracy.
Results
Study population and specimens
In total, 1019 women were asked to participate in the study, of
whom 917 were included and 102 did not meet the inclusion
criteria or declined to participate (Figure 1). Five women were
excluded from the CRT performance evaluation due to either
discrepancy in CRT result between two lab technicians (n=3) or
failure of CRT (n=2).
General characteristics of the 912 women included in the CRT
performance evaluation are shown in Table 1. Their median age
was 30 years (IQR 25–36), 336 (36.9%) were of Creole/Maroon
ethnicity and 229 (25.1%) were of Hindustani ethnicity. Twenty-
one (2.3%) women reported having had sex for money or goods.
Almost all women 900 (98.7%) would wait for the CRT test result
if the test were a standard offering in their clinic. Of these women,
660 (73.3%) would be willing to wait for a maximum of half an
hour to receive the results, the other 240 (26.7%) would be willing
to wait for at least an hour.
Ct prevalence and CRT performance results
Ct prevalence was 20.8% in the high-risk population (visiting
the Dermatological Service) and 9.2% in the low-risk population
(visiting Lobi Foundation). Combining the results of the two sites,
the sensitivity and specificity of the CRT in identifying Ct
compared to NAAT were 41.2% (95% CI, 31.9%–50.9%) and
96.4% (95% CI, 95.0%–97.5%), respectively. PPV of the CRT
was 59.2% (95% CI, 47.5%–70.1%) and NPV was 92.9% (95%
CI, 91.0%–94.5%). Sensitivity and specificity of CRT compared
to NAAT were comparable for the high-risk population (39.4%
and 94.4%) and the low-risk population (42.0% and 96.8%)
(Table 2).
Quantitative load measurements
Quantitative Ct bacterial load and human HLA were assessed
for the samples that showed discrepant results for CRT and
NAAT (n=89) and for samples that were CRT and NAAT
positive (n=42). Ct bacterial load could be detected in 99/131
samples and human HLA in 126/131 samples. Of the 42 samples
Figure 1. Flow chart of specimen collection for the evaluation of a Chlamydia Rapid Test test as diagnostic for urogenital chlamydia
in women at two study sites in Paramaribo, Suriname, from July 2009 to February 2010. NAAT; Aptima chlamydia single test, Genprobe
(control test) CRT; Chlamydia Rapid Test, Diagnostics for the Real World (evaluated test).
doi:10.1371/journal.pone.0032122.g001
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urogenital chlamydia in women at two study sites in Paramaribo, Suriname, from July 2009 to February 2010.
Dermatological Service
(n=159)
Lobi Foundation
(n=753)
Total population
(n=912)
N (%) N (%) N (%)
Median age in years (IQR) 27 (22–34) 30 (25–37) 30 (25–36)
Ethnic Group
Caucasian 5 (3.1) 6 (0.8) 11 (1.2)
Chinese 1 (0.6) 5 (0.7) 6 (0.7)
Creole/Maroon 81 (51.0) 255 (33.9) 336 (36.9)
Hindustani 17 (10.7) 212 (28.2) 229 (25.1)
Indigenous Amerindian 5 (3.1) 9 (1.2) 14 (1.5)
Javanese 10 (6.3) 137 (18.2) 147 (16.1)
Mixed race 39 (24.5) 127 (16.9) 166 (18.2)
Sex for money or goods
Yes 17 (10.7) 4 (0.5) 21 (2.3)
No 140 (88.1) 735 (96.7) 875 (95.9)
Unknown 2 (1.3) 14 (1.9) 16 (1.7)
Willing to wait for POC-Ct test result 159 (100) 741 (98.4) 900 (98.7)
Maximum time these women are willing to wait
Half an hour 84 (52.8) 576 (77.7) 660 (73.3)
At least an hour 75 (47.2) 165 (22.3) 240 (26.7)
Symptoms
Dysuria 56 (35.2) 173 (23.0) 229 (25.1)
Irregular menstruation 53 (33.0) 194 (25.8) 247 (27.1)
Lower abdominal pain 72 (45.3) 302 (40.1) 374 (41.0)
Pain during intercourse 40 (25.2) 192 (25.5) 232 (25.4)
Vaginal discharge 110 (69.2) 369 (49.0) 479 (52.5)
Use of any vaginal cleansing
Yes 80 (50.3) 228 (30.3) 308 (33.8)
No 74 (46.5) 512 (68.0) 586 (64.3)
Unknown 5 (3.1) 13 (1.7) 18 (2.0)
Frequency of cleansing among those who practice vaginal cleansing
At least once a week 43 (53.8) 110 (48.2) 153 (49.7)
Less than once a week 18 (22.5) 56 (24.6) 74 (24.0)
Unknown 19 (23.8) 62 (27.2) 81 (26.3)
IQR; interquartile range.
doi:10.1371/journal.pone.0032122.t001
Table 2. Performance results of the Diagnostics for the Real World Chlamydia Rapid Test (CRT) compared to NAAT (Aptima
chlamydia single test).
Sensitivity (%), 95% CI Specificity (%), 95% CI PPV (%), 95% CI NPV (%), 95% CI
Total population (n=912) 41.2% (42/102), 31.9%–50.9% 96.4% (781/810),
95.0%–97.5%
59.2% (42/71),
47.5%–70.1%
92.9% (781/841),
91.0%–94.5%
Dermatological Service (n=159) 39.4% (13/33), 24.0%–56.6% 94.4 (119/126), 89.3–97.5 65.0 (13/20), 42.7–83.2 85.6 (119/139), 79.0–90.7
Lobi Foundation (n=753) 42.0 (29/69), 30.8–53.9 96.8 (662/684), 95.3–97.9 56.9 (29/51), 43.1–69.9 94.3 (662/702), 92.4–95.8
Evaluation of a CRT as diagnostic for urogenital chlamydia in women at two study sites in Paramaribo, Suriname, from July 2009 to February 2010.
PPV; positive predictive value.
NPV; negative predictive value.
95% CI; 95% confidence interval.
doi:10.1371/journal.pone.0032122.t002
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load was detected in all 42 samples and human HLA in 39
samples. Of the 60 samples that tested CRT negative and NAAT
positive, quantitative Ct bacterial load was detected in 55 samples
and human HLA in all 60 samples. Of the 29 samples that tested
CRT positive and NAAT negative, quantitative Ct bacterial load
was detected in 2 samples and human HLA in 27 samples
(Table 3).
Quantitative Ct bacterial load was 73 times higher in NAAT-
positive/CRT-positive samples (geometric mean 120 IFU) com-
pared to NAAT-positive/CRT-negative samples (geometric mean
1.64 IFU, p,0.001). Human DNA concentration did not differ
between the true-positive and false-negative CRT results
(p=0.835). The average chlamydial/human cell load ratio (Ct
concentration) was 60 times higher in NAAT-positive samples
where CRT detected Ct infection (geometric mean 0.32 IFU/
human cell) compared to loads that CRT did not detect (geometric
mean 0.0053 IFU/human cell, p,0.001). Quantitative HLA load
was comparable for NAAT-positive/CRT-positive samples (geo-
metric mean 344 cells) compared to NAAT-negative/CRT-
positive samples (geometric mean 451 cells, p=0.424).
Quantitative Ct loads were comparable for women reporting
symptoms like vaginal discharge, irregular menstruation, pain
during intercourse, lower abdominal pain or dysuria and women
without the specific symptom (data not shown). Women visiting
the high-risk STI clinic had comparable quantitative Ct loads with
those visiting the low-risk clinic (p=0.525). Sensitivity of the CRT
was comparable for those who practiced any vaginal hygienic
measures, 37.5% (95% CI, 23.6%–53.1%), compared to those
who did not practice vaginal cleansing, 43.3% (95% CI, 31.3%–
56.0%). When comparing women who practice vaginal cleansing
frequently, at least once a week, with those who cleanse less than
once weekly, sensitivity of CRT yields comparable results, 39.1%
(95% CI, 21.1%–59.8%) and 27.3% (95% CI, 7.5%–57.8%),
respectively.
Based on the overall median Ct load, NAAT-positive samples
were divided in two groups with either a low- (range 0.006–12.5
IFU) or high-grade quantitative bacterial Ct load (range 13.5–
6470 IFU). In the low-grade bacterial load group, the CRT
sensitivity was 12.5% (95% CI, 5.2%–24.2%), whereas in the high-
grade Ct load group the sensitivity was 73.5% (95% CI, 59.9%–
84.4%).
Discussion
We found a disappointingly low clinical sensitivity of 42.0% and
39.4% of the CRT in low-risk and high-risk Surinamese women,
respectively, compared to the sensitivity of 86.8% in low-risk
women and 71% in high-risk women in the Philippines, reported
earlier in a study supported by the manufacturer [12]. The
discrepancy might partly be explained by the use of a different
reference test. Where we used Gen-Probe’s Aptima platform as a
reference test, in the Philippines study the Roche Amplicor (Roche
Molecular Systems, Branchburg, NJ) was used. Although current
generation NAATs have comparable sensitivities, NAAT could be
more sensitive than Roche Amplicor [15]. A somewhat lower
sensitivity of CRT in our study could be expected with a more
sensitive control test, but this does not explain the large difference
in sensitivity found in the Philippine study and our results.
Another explanation for the lower sensitivity we found could be
attributed to a different wash-out period for antibiotic use between
the two studies. We excluded women who used antibiotics in the
last 7 days, while in the Philippines study women who used
antibiotics in the previous month were excluded. Time to
clearance of LPS antigen, which is targeted by the CRT, might
be shorter after antibiotic use than time to clearance of Ct rRNA,
which is targeted by NAAT [16]. This could have caused the
occurrence of false-positive NAAT samples, and consequently
more false-negative CRT samples could be expected. Low
sensitivity of the CRT due to inadequate collection resulting in a
low sample yield could be ruled out since the human cell load in
samples with true-positive and false-negative CRT results was
comparable. The CRT had a 96.4% specificity. False-positive
CRT results could have been caused by cross reactivity with C.
ptsittaci or C. pneumoniae as described in the manufacturers manual.
Yet infections with these organisms in the urogenital tract in
humans are uncommon [17,18]. As a false positive chlamydia
diagnosis can have serious adverse social consequences a specificity
of 96,4% is undesirable, especially in low prevalent settings. The
CRT in our study had a few modifications compared to the study
in the Philippines. We used unit dose pipettes instead of unit dose
vials. Also, the nitrocellulose membrane was changed by the
manufacturer and according to the manual, only one dipstick had
to be used to interpret the results. However, when a test is renewed
one might expect at least comparable diagnostic characteristics
compared to the previous test.
Table 3. C. trachomatis quantitative bacterial load and human cell load measurements in concordant and discordant samples with
NAAT (Aptima chlamydia single test) and the Diagnostics for the Real World Chlamydia Rapid Test (CRT).
NAAT+/CRT+ (n=42) NAAT+/CRT (n=60) P-value NAAT2/CRT+ (n=29)
Quantitative Ct load assessed 42 55 2
Geometric mean Ct load (IFU) 119.6 1.6 ,0.001
Range (IFU) 5.57–6470 0.0061–519 0.00261 and 62.9
Quantitative human cell load 39 60 27
Geometric mean human cell load (HLA copy) 344.0 326.7 0.835 451.43
Range human cell load (HLA copy) 5.27–1460 7.99–1930 8.01–7800
Concentration Ct load per human cell assessed (IFU/HLA copy) 39 55 2
Geometric mean of concentration (IFU/HLA copy) 0.32 0.0053 0.001
Range (IFU/HLA copy) 0.0079–107.2 3.9*10
26 – 1.87 1.5*10
26 and 0.15
Evaluation of a CRT as diagnostic for urogenital chlamydia in women at two study sites in Paramaribo, Suriname, from July 2009 to February 2010.
IFU; inclusion forming units.
HLA; human leucocyte antigen gene.
doi:10.1371/journal.pone.0032122.t003
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Ct prevalence was 6.3% in the low-risk group (women visiting an
obstetrics-gynaecology clinic) and 17.9 to 32% in the high-risk
group (female sex workers), which compares well with the
prevalences found in our study, 9.2% and 20.8% respectively.
The sensitivity figures found in our study were comparable for
low-risk and high-risk women, 42.0% and 39.4% respectively.
Quite surprisingly, in the Philippines study a much lower
sensitivity was found in the high-risk group compared to the
low-risk group. The authors explain this finding as a result of the
use of vaginal creams and other feminine hygiene products, which
can interfere with the CRT. In our study, the sensitivity of CRT
was comparable for women who practiced any vaginal cleansing
and those who did not.
Although we consider the population recruited at Lobi
Foundation a low risk group, with a prevalence of 9.2% this
population would be considered high risk in many settings. Yet,
with a prevalence of 20.8% as found at the Dermatological
Service, the difference in prevalence between the two study sites is
substantial.
The sensitivity of CRT is higher in samples with a high bacterial
load. The clinical relevance of organism load is still debated, but it
is suggested that infections with high organism loads are more
likely to lead to cervicitis or PID and are associated with multiple
patient-reported symptoms [19]. However, the association with
patient-reported symptoms was only found with first-void urine
and endocervical samples and not with self-collected vaginal
samples. In our study, where nurse-collected vaginal swabs were
used, quantitative Ct loads were not significantly different for
asymptomatic women and women reporting one or multiple
symptoms such as vaginal discharge or dysuria.
The NAAT platform is a latest generation highly sensitive
commercial diagnostic test for Ct [20]. However no test is 100%
accurate and a positive bacterial Ct load signal was detected in two
samples that were NAAT negative and CRT positive. One sample
had a Ct load of 62.9 IFU which might be explained by inhibition
of high target load [21]. The other sample had a very low load of
0.00261 IFU. Since the frequency of these discrepancies was
extremely low, we do not consider that this finding significantly
affects our test evaluation.
A recent field study of the same CRT test but to detect ocular
chlamydia infection (trachoma) found similar disappointingly low
sensitivity (33.3%–67.9%) and specificity (92.4%–99.0%) [22].
Most commercially available and clinically evaluated POC tests
for urogenital chlamydia show poor sensitivity results [10].
Compared with the results found in our evaluation, the CRT of
Diagnostics for the Real World outperforms some of the other
commercially available products [10]. Still, with a sensitivity of
only 41.7%, this test performs under the minimally required
sensitivity of 63% required for a POC test to treat more infected
individuals than the standard NAAT in a setting with low patient
return (,65%), [8]. On the other hand, in situations where
transmission during treatment delay and low return for treatment
are considerable, even a POC test with a sensitivity below 63%
could be beneficial in the prevention of ongoing STI transmission
[23]. A recent economic evaluation analysis using the same CRT
as we evaluated in this study, showed that in the UK using NAAT
is more cost-effective. [24]. In that evaluation, a sensitivity
between 73% and 85% for the CRT was assumed.
POC tests available for systemic infections like HIV and syphilis
are highly sensitive since they are based on the detection of serum
antibodies [25,26]. Infections caused by organisms like Ct (but also
N. gonorrhoeae) are confined to mucosal tissue and normally invoke
little to no production of antibodies. Therefore, the development
of POC tests to diagnose mucosal Ct infections based on the
detection of serum antibodies is, at least for now, not an option.
Improved POC tests for Ct need to detect bacterial antigens or
nucleic acids, even in cases with a low bacterial load. Promising
steps have been made in the field of POC HIV-load NAAT using
nanotechnology [27]. Along the same lines, a POC test for
urogenital chlamydia with sufficient sensitivity could be developed.
Until reliable and affordable diagnostics are available, algorithms
for syndromic management can be used for low-resource settings,
although the success of algorithms for vaginal discharge varies
between populations [28].
In conclusion, the evaluated CRT of Diagnostics for the Real
World has no added value in the management of Ct infections due
to its low test performance. There is an urgent need for POC
diagnostics for the detection of urogenital chlamydia meeting the
ASSURED criteria, including adequate sensitivity.
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